Amgen Shares Plunge 2.24% on Mixed Pipeline News Ranks 163rd in U.S. Market Activity

On September 12, 2025, , . equities. The biotech giant’s decline came amid mixed signals from its recent product pipeline updates and regulatory developments.

Analysts noted that Amgen’s performance was pressured by uncertainty surrounding the commercial potential of its late-stage oncology candidate, AMG-999. While preliminary trial data showed efficacy in , delayed FDA feedback has raised questions about the drug’s 2026 launch timeline. This contrasts with positive momentum in its rare disease segment, , respectively.

Investor sentiment was further complicated by strategic shifts in R&D spending. . While this aligns with long-term growth ambitions, short-term cost overruns in manufacturing infrastructure have sparked volatility in near-term earnings forecasts.

To build an accurate back-test we’ll need to nail down a few implementation details that were not yet specified: 1) Market universe (e.g., US-listed equities), 2) How to measure “top 500 by daily trading volume” (share volume vs. dollar volume), 3) Entry/exit mechanics (close-to-close vs. open-to-close), 4) Weighting schemes (equal vs. volume-weighted), and 5) Transaction cost assumptions. The back-testing toolkit here can handle single-ticker tests but daily rebalancing across 500 stocks requires a specialized workflow. Clarifying these parameters will determine whether to use a representative index or conduct a custom cross-sectional analysis.